179 related articles for article (PubMed ID: 36090975)
1. Targeting the Cbl-b-Notch1 axis as a novel immunotherapeutic strategy to boost CD8+ T-cell responses.
Monticone G; Huang Z; Csibi F; Leit S; Ciccone D; Champhekar AS; Austin JE; Ucar DA; Hossain F; Ibba SV; Boulares AH; Carpino N; Xu K; Majumder S; Osborne BA; Loh C; Miele L
Front Immunol; 2022; 13():987298. PubMed ID: 36090975
[TBL] [Abstract][Full Text] [Related]
2. Deficiency of the T cell regulator Casitas B-cell lymphoma-B aggravates atherosclerosis by inducing CD8+ T cell-mediated macrophage death.
Seijkens TTP; Poels K; Meiler S; van Tiel CM; Kusters PJH; Reiche M; Atzler D; Winkels H; Tjwa M; Poelman H; Slütter B; Kuiper J; Gijbels M; Kuivenhoven JA; Matic LP; Paulsson-Berne G; Hedin U; Hansson GK; Nicolaes GAF; Daemen MJAP; Weber C; Gerdes N; de Winther MPJ; Lutgens E
Eur Heart J; 2019 Jan; 40(4):372-382. PubMed ID: 30452556
[TBL] [Abstract][Full Text] [Related]
3. Flavone inhibited proliferation of T-ALL by promoting c-Cbl-induced ubiquitinylation and degradation of Notch1.
Zhu W; Zhu Y; Xu H; Wang T; Wang J; Meng M; Liu Y; Yan H; Yang Q; Liu P
Biochem Biophys Res Commun; 2020 Feb; 522(3):684-689. PubMed ID: 31785807
[TBL] [Abstract][Full Text] [Related]
4. Deletion of Cbl-b inhibits CD8
Kumar J; Kumar R; Kumar Singh A; Tsakem EL; Kathania M; Riese MJ; Theiss AL; Davila ML; Venuprasad K
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462140
[TBL] [Abstract][Full Text] [Related]
5. Notch1 signaling in melanoma cells promoted tumor-induced immunosuppression via upregulation of TGF-β1.
Yang Z; Qi Y; Lai N; Zhang J; Chen Z; Liu M; Zhang W; Luo R; Kang S
J Exp Clin Cancer Res; 2018 Jan; 37(1):1. PubMed ID: 29301578
[TBL] [Abstract][Full Text] [Related]
6. Inhibiting Notch1 enhances immunotherapy efficacy in melanoma by preventing Notch1 dependent immune suppressive properties.
Qiu H; Zmina PM; Huang AY; Askew D; Bedogni B
Cancer Lett; 2018 Oct; 434():144-151. PubMed ID: 30036609
[TBL] [Abstract][Full Text] [Related]
7. Targeting Cbl-b in cancer immunotherapy.
Augustin RC; Bao R; Luke JJ
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36750253
[TBL] [Abstract][Full Text] [Related]
8. Abrogating Cbl-b in effector CD8(+) T cells improves the efficacy of adoptive therapy of leukemia in mice.
Stromnes IM; Blattman JN; Tan X; Jeevanjee S; Gu H; Greenberg PD
J Clin Invest; 2010 Oct; 120(10):3722-34. PubMed ID: 20890046
[TBL] [Abstract][Full Text] [Related]
9. Cbl-b Deficiency Mediates Resistance to Programmed Death-Ligand 1/Programmed Death-1 Regulation.
Fujiwara M; Anstadt EJ; Clark RB
Front Immunol; 2017; 8():42. PubMed ID: 28184224
[TBL] [Abstract][Full Text] [Related]
10. Spontaneous tumor rejection by cbl-b-deficient CD8+ T cells.
Loeser S; Loser K; Bijker MS; Rangachari M; van der Burg SH; Wada T; Beissert S; Melief CJ; Penninger JM
J Exp Med; 2007 Apr; 204(4):879-91. PubMed ID: 17403934
[TBL] [Abstract][Full Text] [Related]
11. β-Adrenergic Signaling Impairs Antitumor CD8
Nissen MD; Sloan EK; Mattarollo SR
Cancer Immunol Res; 2018 Jan; 6(1):98-109. PubMed ID: 29146881
[TBL] [Abstract][Full Text] [Related]
12. Notch1 gene mutations target KRAS G12D-expressing CD8+ cells and contribute to their leukemogenic transformation.
Kong G; Du J; Liu Y; Meline B; Chang YI; Ranheim EA; Wang J; Zhang J
J Biol Chem; 2013 Jun; 288(25):18219-27. PubMed ID: 23673656
[TBL] [Abstract][Full Text] [Related]
13. Overproduction of IFNγ by Cbl-b-Deficient CD8+ T Cells Provides Resistance against Regulatory T Cells and Induces Potent Antitumor Immunity.
Han S; Liu ZQ; Chung DC; Paul MS; Garcia-Batres CR; Sayad A; Elford AR; Gold MJ; Grimshaw N; Ohashi PS
Cancer Immunol Res; 2022 Apr; 10(4):437-452. PubMed ID: 35181779
[TBL] [Abstract][Full Text] [Related]
14. Diacylglycerol kinase ζ (DGKζ) and Casitas b-lineage proto-oncogene b-deficient mice have similar functional outcomes in T cells but DGKζ-deficient mice have increased T cell activation and tumor clearance.
Wesley EM; Xin G; McAllister D; Malarkannan S; Newman DK; Dwinell MB; Cui W; Johnson BD; Riese MJ
Immunohorizons; 2018 Apr; 2(4):107-118. PubMed ID: 30027154
[TBL] [Abstract][Full Text] [Related]
15. Distinct sensitivity of CD8+ CD4- and CD8+ CD4+ leukemic cell subpopulations to cyclophosphamide and rapamycin in Notch1-induced T-ALL mouse model.
Zhang Y; Hua C; Cheng H; Wang W; Hao S; Xu J; Wang X; Gao Y; Zhu X; Cheng T; Yuan W
Leuk Res; 2013 Nov; 37(11):1592-601. PubMed ID: 24090996
[TBL] [Abstract][Full Text] [Related]
16. CD4
Xiao M; Xie L; Cao G; Lei S; Wang P; Wei Z; Luo Y; Fang J; Yang X; Huang Q; Xu L; Guo J; Wen S; Wang Z; Wu Q; Tang J; Wang L; Chen X; Chen C; Zhang Y; Yao W; Ye J; He R; Huang J; Ye L
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580929
[TBL] [Abstract][Full Text] [Related]
17. Activation of Notch1 promotes development of human CD8(+) single positive T cells in humanized mice.
Haji Y; Suzuki M; Moriya K; So T; Hozumi K; Mizuma M; Unno M; Ishii N
Biochem Biophys Res Commun; 2014 May; 447(2):346-51. PubMed ID: 24726647
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of tumor-infiltrating immune cells focusing on BTLA and Cbl-b in patients with gallbladder cancer.
Oguro S; Ino Y; Shimada K; Hatanaka Y; Matsuno Y; Esaki M; Nara S; Kishi Y; Kosuge T; Hiraoka N
Cancer Sci; 2015 Dec; 106(12):1750-60. PubMed ID: 26395180
[TBL] [Abstract][Full Text] [Related]
19. Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8
Mastelic-Gavillet B; Navarro Rodrigo B; Décombaz L; Wang H; Ercolano G; Ahmed R; Lozano LE; Ianaro A; Derré L; Valerio M; Tawadros T; Jichlinski P; Nguyen-Ngoc T; Speiser DE; Verdeil G; Gestermann N; Dormond O; Kandalaft L; Coukos G; Jandus C; Ménétrier-Caux C; Caux C; Ho PC; Romero P; Harari A; Vigano S
J Immunother Cancer; 2019 Oct; 7(1):257. PubMed ID: 31601268
[TBL] [Abstract][Full Text] [Related]
20. Rescue of notch-1 signaling in antigen-specific CD8+ T cells overcomes tumor-induced T-cell suppression and enhances immunotherapy in cancer.
Sierra RA; Thevenot P; Raber PL; Cui Y; Parsons C; Ochoa AC; Trillo-Tinoco J; Del Valle L; Rodriguez PC
Cancer Immunol Res; 2014 Aug; 2(8):800-11. PubMed ID: 24830414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
